tiprankstipranks
Advertisement

XMHQ - ETF AI Analysis

Compare

Top Page

XMHQ

Invesco S&P MidCap Quality ETF (XMHQ)

Rating:74Outperform
Price Target:
XMHQ, the Invesco S&P MidCap Quality ETF, earns a solid overall rating thanks to several strong mid-cap holdings with healthy financial performance and positive growth outlooks, such as United Therapeutics and NEXTracker, which show robust revenue trends, strategic initiatives, and supportive technical signals. Other key positions like Medpace Holdings and Exelixis further boost the fund’s quality profile with strong earnings and constructive momentum, though frequent mentions of high valuations and occasional bearish or overbought technical signals across several holdings highlight a main risk that some stocks may be priced aggressively and could be more volatile. Overall, the ETF’s rating reflects a portfolio tilted toward fundamentally strong, growing companies, balanced by the risk that many of them trade at demanding valuations.
Positive Factors
Strong Leading Holding
The largest position, TechnipFMC, has shown very strong gains this year, giving the fund a performance boost.
Broad Sector Mix
Holdings spread across industrials, health care, financials, technology, and other sectors help reduce reliance on any single industry.
Moderate Costs for an Active Tilt
The expense ratio is modest for a rules-based ETF that targets higher-quality mid-cap stocks, allowing investors to keep more of their returns.
Negative Factors
Concentrated in Top Positions
A meaningful share of assets is in a small group of stocks, so weakness in these names could noticeably affect the fund.
Mixed Performance Among Key Holdings
Some important positions, such as Medpace Holdings, have shown weak results this year, which can drag on overall performance.
Heavy U.S.-Only Exposure
With virtually all assets in U.S. companies, the fund offers little geographic diversification if the U.S. market struggles.

XMHQ vs. SPDR S&P 500 ETF (SPY)

XMHQ Summary

The Invesco S&P MidCap Quality ETF (XMHQ) invests in medium‑sized U.S. companies that score well on measures of financial strength and stability. It follows the S&P MidCap 400 Quality Index, which looks for businesses with strong profits and manageable debt. The fund holds a mix of sectors like industrials, health care, and technology, with companies such as Illumina and Twilio among its top positions. Someone might invest in XMHQ to seek long-term growth and diversification away from only large, well-known stocks. A key risk is that mid-cap stocks can be more volatile and can go up and down sharply with the market.
How much will it cost me?The Invesco S&P MidCap Quality ETF (XMHQ) has an expense ratio of 0.25%, meaning you’ll pay $2.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it tracks a specialized index focused on mid-cap companies with strong quality metrics. It’s designed to offer targeted exposure to financially healthy mid-cap stocks.
What would affect this ETF?The Invesco S&P MidCap Quality ETF (XMHQ) could benefit from economic growth in the U.S., particularly in sectors like Industrials and Health Care, which make up a significant portion of its holdings. However, rising interest rates or economic slowdowns could negatively impact mid-cap companies, especially those in cyclical sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in sector-specific trends could also influence the performance of its top holdings, such as Comfort Systems and Medpace Holdings.

XMHQ Top 10 Holdings

XMHQ is leaning heavily into U.S. industrials and quality mid-cap growth stories, with names like nVent Electric and Carpenter Technology doing much of the heavy lifting as their shares have been on a strong upward climb. Illumina and Curtiss-Wright are also rising, giving the fund an extra boost from health care and defense-linked industrials. On the flip side, TechnipFMC and Medpace have been more mixed lately, occasionally taking some wind out of the ETF’s sails. Overall, it’s a U.S.-centric, industrials-tilted portfolio riding a mid-cap quality wave.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
TechnipFMC4.22%$228.45M$28.71B120.13%
80
Outperform
Illumina3.96%$214.66M$28.78B94.14%
71
Outperform
Curtiss-Wright3.22%$174.47M$26.44B45.08%
74
Outperform
nVent Electric2.97%$160.62M$24.85B98.95%
76
Outperform
Medpace Holdings2.96%$160.46M$15.36B72.42%
79
Outperform
Everpure2.94%$159.47M$22.73B19.42%
64
Neutral
Carpenter Technology2.92%$157.96M$27.55B94.06%
75
Outperform
Exelixis2.88%$155.77M$14.00B25.75%
78
Outperform
United Therapeutics2.62%$142.03M$22.46B83.44%
79
Outperform
Evercore Partners2.47%$133.56M$13.53B14.41%
76
Outperform

XMHQ Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
110.75
Positive
100DMA
108.04
Positive
200DMA
106.16
Positive
Market Momentum
MACD
0.71
Positive
RSI
53.29
Neutral
STOCH
38.24
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 112.39, equal to the 50-day MA of 110.75, and equal to the 200-day MA of 106.16, indicating a bullish trend. The MACD of 0.71 indicates Positive momentum. The RSI at 53.29 is Neutral, neither overbought nor oversold. The STOCH value of 38.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XMHQ.

XMHQ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$5.42B0.25%
74
Outperform
$7.52B0.23%
69
Neutral
$7.42B0.35%
73
Outperform
$5.88B0.41%
70
Outperform
$3.97B0.38%
70
Neutral
$3.77B0.07%
70
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XMHQ
Invesco S&P MidCap Quality ETF
112.62
14.37
14.63%
FMDE
Fidelity Enhanced Mid Cap ETF
XMMO
Invesco S&P MidCap Momentum ETF
JHMM
John Hancock Multifactor Mid Cap ETF
DON
WisdomTree U.S. MidCap Dividend Fund
IVOO
Vanguard S&P Mid-Cap 400 ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement